End-of-day quote
Shenzhen S.E.
03:30:00 31/05/2024 am IST
|
5-day change
|
1st Jan Change
|
2.36
CNY
|
-4.84%
|
|
-22.37%
|
-76.40%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,243
|
5,154
|
3,356
|
6,460
|
4,458
|
4,005
|
Enterprise Value (EV)
1 |
1,849
|
4,751
|
2,945
|
6,032
|
4,054
|
3,672
|
P/E ratio
|
162
x
|
-223
x
|
284
x
|
2,095
x
|
-79.4
x
|
-56.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.68
x
|
18.7
x
|
13.2
x
|
9.2
x
|
36.3
x
|
46.2
x
|
EV / Revenue
|
5.5
x
|
17.3
x
|
11.6
x
|
8.59
x
|
33
x
|
42.4
x
|
EV / EBITDA
|
97.7
x
|
387
x
|
156
x
|
440
x
|
-159
x
|
-84.8
x
|
EV / FCF
|
-940
x
|
164
x
|
-77.9
x
|
160
x
|
-141
x
|
-71.1
x
|
FCF Yield
|
-0.11%
|
0.61%
|
-1.28%
|
0.63%
|
-0.71%
|
-1.41%
|
Price to Book
|
3.46
x
|
8.26
x
|
5.28
x
|
10.1
x
|
7.65
x
|
7.82
x
|
Nbr of stocks (in thousands)
|
4,00,500
|
4,00,500
|
4,00,500
|
4,00,500
|
4,00,500
|
4,00,500
|
Reference price
2 |
5.600
|
12.87
|
8.380
|
16.13
|
11.13
|
10.00
|
Announcement Date
|
12/03/19
|
28/04/20
|
14/04/21
|
29/04/22
|
20/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
336
|
275.3
|
254
|
702.5
|
123
|
86.62
|
EBITDA
1 |
18.91
|
12.26
|
18.82
|
13.72
|
-25.42
|
-43.28
|
EBIT
1 |
-3.859
|
-13.91
|
-9.432
|
-16.88
|
-55
|
-73.66
|
Operating Margin
|
-1.15%
|
-5.05%
|
-3.71%
|
-2.4%
|
-44.73%
|
-85.04%
|
Earnings before Tax (EBT)
1 |
15.68
|
-22.39
|
7.313
|
-5.564
|
-68.73
|
-82.24
|
Net income
1 |
13.87
|
-23.11
|
11.81
|
3.093
|
-56.12
|
-70.94
|
Net margin
|
4.13%
|
-8.39%
|
4.65%
|
0.44%
|
-45.64%
|
-81.9%
|
EPS
2 |
0.0346
|
-0.0577
|
0.0295
|
0.007700
|
-0.1401
|
-0.1771
|
Free Cash Flow
1 |
-1.967
|
29.03
|
-37.78
|
37.75
|
-28.73
|
-51.63
|
FCF margin
|
-0.59%
|
10.54%
|
-14.87%
|
5.37%
|
-23.37%
|
-59.6%
|
FCF Conversion (EBITDA)
|
-
|
236.68%
|
-
|
275.07%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
1,220.36%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/19
|
28/04/20
|
14/04/21
|
29/04/22
|
20/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
394
|
404
|
412
|
428
|
403
|
333
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.97
|
29
|
-37.8
|
37.8
|
-28.7
|
-51.6
|
ROE (net income / shareholders' equity)
|
2.12%
|
-3.62%
|
1.13%
|
-1.08%
|
-11.5%
|
-14.7%
|
ROA (Net income/ Total Assets)
|
-0.31%
|
-1.09%
|
-0.72%
|
-1.26%
|
-4.37%
|
-6.68%
|
Assets
1 |
-4,524
|
2,119
|
-1,652
|
-244.7
|
1,285
|
1,062
|
Book Value Per Share
2 |
1.620
|
1.560
|
1.590
|
1.600
|
1.460
|
1.280
|
Cash Flow per Share
2 |
0.9600
|
0.4900
|
0.3100
|
0.2500
|
0.4800
|
0.5300
|
Capex
1 |
15.5
|
7.07
|
23.6
|
10.4
|
25.2
|
15.7
|
Capex / Sales
|
4.62%
|
2.57%
|
9.29%
|
1.47%
|
20.51%
|
18.08%
|
Announcement Date
|
12/03/19
|
28/04/20
|
14/04/21
|
29/04/22
|
20/04/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -76.40% | 131M | | +15.91% | 41.97B | | +22.40% | 22.34B | | +18.48% | 15.25B | | +16.12% | 14B | | +45.12% | 12.06B | | -0.05% | 6.79B | | -9.58% | 6.8B | | -8.87% | 5.73B | | +14.18% | 5.49B |
Generic Pharmaceuticals
|